表紙
市場調查報告書

鼻腔給藥的美國市場

Intranasal Drug Delivery

出版商 Global Industry Analysts, Inc. 商品編碼 243057
出版日期 內容資訊 英文 239 Pages
商品交期: 最快1-2個工作天內
價格
鼻腔給藥的美國市場 Intranasal Drug Delivery
出版日期: 2019年01月01日內容資訊: 英文 239 Pages
簡介

本報告提供美國的鼻腔給藥市場相關調查分析,過敏感染疾病,止痛,骨質疏鬆症,疫苗接種為對象,市場成果與預測,主要企業簡介等系統性資訊。

第1章 簡介,調查手法,產品定義

第2章 美國市場分析

  • 產業概要
    • 序文
    • 鼻子:跨越血腦障壁有吸引力的途徑
    • 生物有效性:鼻腔給藥的重要方面
    • 預測
    • 鼻腔給藥器材和設備
    • 傳統 vs. 先進的經鼻藥
  • 推動市場要素、趨勢、問題點
    • 高齡化經鼻藥療法的需求劇增
    • 專利懸崖提供新的機會
  • 最近的研究、開發主張
  • 技術概要
  • 經鼻藥:概要
  • 產品開發、核准、介紹
  • 近來產業活動
  • 主要企業
    • Aegis Therapeutics LLC (美國)
    • AptarGroup, Inc. (美國)
    • AstraZeneca Plc. (英國)
    • Becton Dickinson and Company (美國)
    • GlaxoSmithKline Plc. (英國)
    • Johnson & Johnson Inc. (美國)
    • Marina Biotech, Inc. (美國)
    • Merck & Co., Inc. (美國)
    • Nemera (法國)
    • Novartis AG (瑞士)
    • OptiNose US Inc. (美國)
    • Pfizer, Inc. (美國)
    • Valeant Pharmaceuticals International, Inc. (加拿大)
  • 美國市場分析

第3章 競爭情形

  • 企業簡介:64家公司 (包含事業部/子公司有81家)
    • 美國
    • 加拿大
    • 日本
    • 歐洲
    • 亞太地區 (日本以外)
    • 中東
    • 南美

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1795

This report analyzes the US Market for Intranasal Drug Delivery in US$ Million by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 64 companies including many key and niche players such as -

Aegis Therapeutics LLC
AptarGroup, Inc.
AstraZeneca Plc
Becton Dickinson and Company
GlaxoSmithKline Plc
Johnson & Johnson Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definition and Scope of Study

II. A US MARKET REPORT

1. INDUSTRY OVERVIEW

  • A Prelude
  • Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier
  • Factors Inhibiting Nose-to-Brain Transportation of Drugs
    • Drug's Physico-Chemical Properties
    • Drug Dose, Concentration & Volume Administration
    • Mucociliary Clearance
    • Existence of Enzymatic Activity
    • Animal Species: Variations in Nasal Mucosa
  • Overcoming Barriers to Nose-to-Brain Delivery of Drugs
    • Prodrug Technique
    • Innovative Formulation
    • Use of Enzyme Inhibitors & Absorption Enhancers
  • Bioavailability: An Important Facet of Intranasal Drug Delivery
  • Chemical Modification
  • Transient Modification & Limited Enzymatic Activity
  • Bioavailability of Large Molecules
  • Bio-Adhesive Polymers: Useful in Increasing Drug Absorption
  • Outlook
  • Nasal Drug Delivery Devices & Equipment
  • Preservative Free Systems (PFS)
  • Traditional Vs. Advanced Intranasal Drug Formulation Types
  • Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application

2. MARKET DRIVERS, TRENDS & ISSUES

  • Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies
    • Table 1: Global Population Estimates (in Billion): 2000-2050P (includes corresponding Graph/Chart)
    • Table 2: Aging (65+) Demographics as a Percentage of Total Population for Major Countries: 2010, 2015 & 2020 (includes corresponding Graph/Chart)
    • Table 3: Global Aging Population (in Thousands) by Age Group: 2010, 2015, 2025 & 2050 (includes corresponding Graph/Chart)
    • Table 4: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2015 (includes corresponding Graph/Chart)
    • Table 5: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
    • Table 6: Life Expectancy for Select Countries in Number of Years: 2015 (includes corresponding Graph/Chart)
    • Table 7: US Geriatric Population by Age Group (2000, 2005, 2010, 2015, 2020, 2030, 2040, & 2050): Percentage Share of US Population of Senior Citizens of Age Group 65-74 Years, 75- 84 Years, and 85 Years & Above (includes corresponding Graph/Chart)
  • Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era
    • Table 8: Top Nasal Inhalers, Sprays, and Drops Brands in the US (2017): Percentage Share Breakdown of Dollar Sales for Afrin No Drip, Afrin, Arm & Hammer Simply Saline, Zicam, Neilmed Sinus Rinse, Ayr, Private Labels, and Others (includes corresponding Graph/Chart)
  • Pharmaceutical and Medical Device Companies Vying to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients
    • Table 9: Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries: 2016 (includes corresponding Graph/Chart)
    • Table 10: The US Allergic Rhinitis Patient Population by Disease Severity (2016): Percentage Breakdown of Patient Pool for Mild Intermittent, Mild Persistent, Moderate-severe Intermittent, and Moderate-severe Persistent (includes corresponding Graph/Chart)
    • The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
    • The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
    • Table 11: Global Respiratory Drugs Market by Category (2015 & 2020): Percentage Breakdown of Dollar Values for COPD Therapies, Inhaled Steroids, Long Acting Beta Agonists, Nasal Steroids, and Others (includes corresponding Graph/Chart)
    • The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
    • The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
  • Intranasal Corticosteroids - A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease
    • Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage
  • Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight
  • Innovation in Drug Delivery: A Talisman for Success
  • Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications
  • Controlled Release Technology Is the Buzz Word
  • Target-Specific Delivery Devices: Of Critical Value
  • Safety and Cost: Primary Growth Drivers
  • Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery
  • Intranasal Therapeutics Delivery - A High Potential Method for Treating CNS Diseases
  • Intranasal Insulin Delivery Offers Strong Clinical Significance
    • Inhaled Insulin Market Challenged by Low Acceptance Levels
  • Intranasal Delivery of Anti-emetic Agent Metoclopramide Hydrochloride Validated by Study on Rodents
  • Intranasal Delivery of Peptide-Based Pharmaceuticals
    • Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace
  • Tight Junction Biology: A Key Speed Breaker in Commercialization
  • RNA Interference (RNAi): A Tool to Manipulate Tight Junctions
  • Research Studies Authenticate Benefits of Bi-Directional Nasal Drug Delivery
  • Growing Interest for Preservative-free Nasal Spray Formulations
  • Multi-Dose Containers Developed to Offer Resistance against Microbial Contamination

3. RECENT RESEARCH & DEVELOPMENT INITIATIVES

  • OptiNose XHANCE
  • Nose-to-Brain Drug Delivery
  • OPN-300 - A Potential Alternative for Many Brain Disorders
  • Orexin-A Replacement for Treating Nacrolepsy
  • Advanced Nanoparticle Nasal Spray to Enable Drug Delivery to Brain
  • OptiNose Develops Innovative Treatment Option for Sinusitis
  • Intranasal Administration of ATX-LIPO for Brain Targeting - A Promising Therapy for ADHD
  • Noteworthy Registered and Published Clinical Trials on Intranasal Psychotropics
  • Focused Ultrasound Leveraged to Enhance Intranasal Drug Delivery
  • Evoke Pharma Develops EVK-001 Intranasal Metoclopramide Delivery System for Treating Gastroparesis
  • Smart Polymers with Temperature, pH or Ionic Response in Nasal drug Delivery
  • Chitosan Thermosensitive Biogels Evaluated for Intranasal Delivery of CNS Drugs
    • Select Nasal Drug Absorption Enhancers and Related Mechanisms
  • Dendrimers to Enhance Water-solubility of Antipsychotic Drugs for Intranasal Administration
  • Naloxone Hydrochloride Nasal Sprays Provides a Powerful Alternative for Opioid Overdose Medications
  • OptiNose ONZETRA Xsail (AVP-825) - An Innovative Breath-Powered Intranasal Delivery System for Migraine Treatment
  • Clinical Study Demonstrates Faster Antidepression Effects of Intranasal Ketamine
  • Intranasal Aerosol Dose of PH94B Investigated for Treating Social Anxiety Disorder (SAD)

4. TECHNOLOGY OVERVIEW

  • Intranasal Drug Delivery: A Descriptive Exposition
  • Nasal Physiology
  • Challenges Involved In Formulating Nasal Drugs
    • The Importance of Bioadhesion
      • Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range
  • Intranasal Drugs - Prescription (Rx) and Over-the-Counter (OTC)
  • Differences between Systemic Delivery and Local Effects
  • Nasal Powders Vs. Sprays
  • Nasal Drug Delivery Devices
  • Types of Drug Delivery Devices
    • Droppers
    • Sprays
    • Aerosol Containers/Inhalers
    • Pumps
    • Nasal Aspirators
  • Intranasal Drug Delivery Vis-a-vis Other Delivery Techniques
  • Limitations of Intranasal Drug Delivery
  • Allergy
  • Definition
  • Symptoms
  • Allergic Rhinitis
  • Nasal Allergies

5. NASAL DELIVERED DRUGS: AN OVERVIEW

  • Nasal Drugs for Allergies
  • Corticosteroid Nasal Sprays
    • Flonase
    • Patanase
    • Beconase
    • Other Nasal Corticosteroid Drugs
  • Antihistamine Nasal Sprays
    • Astelin Nasal Spray
    • Otrivin Nasal Spray
    • Livostin Nasal Spray
    • Other Nasal Antihistamine Drugs
      • Select Brands of Allergy Relievers
  • Nasal Drugs for Postmenopausal Osteoporosis
  • Calcitonin-Salmon Nasal Spray
  • Miacalcin Nasal Spray
  • Fortical(r) Nasal Spray
  • Intranasal Pain Management Drugs
  • Stadol Nasal Spray
  • Imitrex
  • Migranal
  • Zolmitriptan Nasal Spray
    • Intranasal Analgesics for Treating Migraine
  • Intranasal Vaccination
  • Process of Intranasal Immunization
  • "LAIV" Nasal Spray Flu Vaccine
  • FluMist(r) Vaccine from MedImmune
  • Intranasal Drugs for Sexual Dysfunction
  • Nasal Spray for Treating Vitamin B12 Deficiency
  • Nasal Spray for Aiding Smoking Cessation

6. PRODUCT DEVELOPMENTS, APPROVALS & INTRODUCTIONS

  • FDA Approves OptiNose XHANCE(tm) Nasal Spray
  • Splintek Launches Intra-Nasal Sleep Inhaler
  • Allergan Receives Market Authorization for TrueTear(tm)
  • St. Renatus Launches Kovanaze(tm) Nasal Spray
  • Perrigo and West-Ward Pharmaceuticals Launch Generic Store Brand Flonase(r)
  • Nemera Launches Advancia Multi-Dose Nasal Spray System
  • Adapt Pharma Launches Narcan Opioid Antagonist
  • Apotex Unveils Generic Version of Nasonex(r)
  • McNeil Consumer Healthcare Rolls Out OTC RHINOCORT(r)
  • OptiNose Bags FDA Approval for ONZETRA(tm) Xsail(tm)
  • Avanir's Onzetra Secures FDA Approval
  • FDA Approves Lannett's Sumatriptan Nasal Spray
  • Meda's Dymista Bags Health Canada's Approval
  • Endo Pharmaceuticals Announces Availability of NATESTO
  • AstraZenca Canada Unveils FluMist for Children
  • Perrigo Receives US FDA Approval for Generic Version of Sun Pharma's Kenalog
  • GSK Rolls Out OTC Version of Flonase Allergy Relief
  • Upsher-Smith Publishes Data from USL261 Phase 1 Trials
  • KemPharm Concludes KP201/APAP's Human Abuse Liability Program
  • OptiNose Publishes Results of OPN 375's Phase III Trial
  • NanoBio's Genital Herpes Vaccine Proven Effective
  • Recro Pharma Releases Further Details of Dex-IN's Phase II Clinical Trial
  • Evoke Announces Phase III Trials of EVK-001
  • FDA Accepts Filing of TARSA's TBRIA
  • FDA Accepts Review of Pfizer's ALO-02
  • Breckenridge Bags FDA Approval for Azelastine HCl Nasal Solution
  • ZOMIG(r) Gets FDA Approval

7. RECENT INDUSTRY ACTIVITY

  • Opiant Pharmaceuticals to Pursue Development of Intranasal Nalmefene
  • Egalet and OraPharma to Co-Promote SPRIX Nasal Spray
  • Aegis Develops Hydromorphone Nasal Spray
  • Emergent Biosolutions to Develop Intranasal Spray for Treatment of Cyanide Poisoning
  • Aptar Pharma to Manufacture Child-Resistant Nasal Pumps in North America
  • Therapix and Yissum Sign License for Cannabinoid Nasal Drug Delivery Technology
  • Impel NeuroPharma and Camargo Pharmaceutical Services Sign Service Agreements
  • Egalet Inks Deal With Septodont for SPRIX(r) Promotion
  • Lilly Acquires Intranasal Glucagon Rights
  • UAE recalls Otrivin Nasal Spray Batches
  • Eli Lily Acquires Rights for Innovent's Intranasal Glucagon
  • AstraZenca Commences Shipment of FluMist(r)

8. FOCUS ON SELECT PLAYERS

  • Aegis Therapeutics LLC (USA)
  • AptarGroup, Inc. (USA)
  • AstraZeneca Plc. (UK)
  • MedImmune, Inc. (USA)
  • Becton Dickinson and Company (USA)
  • GlaxoSmithKline Plc. (UK)
  • Johnson & Johnson Inc. (USA)
  • Marina Biotech, Inc. (USA)
  • Merck & Co., Inc. (USA)
  • Nemera (France)
  • Novartis AG (Switzerland)
  • OptiNose US Inc. (USA)
  • Pfizer, Inc. (USA)
  • Valeant Pharmaceuticals International, Inc. (Canada)

9. US MARKET ANALYTICS

    • Table 12: The US Recent Past, Current & Future Analysis for Intranasal Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 13: The US Historic Review for Intranasal Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 14: The US 14-Year Perspective for Intranasal Drug Delivery by Therapeutic Area - Percentage Breakdown of Values Sales for Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)